This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)

Tipranks - Tipranks - Tue Jun 9, 6:52AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX).

Introducing TipRanks MCP for Agents

Gilead Sciences (GILD)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences today and set a price target of $122.00. The company’s shares closed last Friday at $129.16.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 10.1% and a 51.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Aardvark Therapeutics, Inc., and MoonLake Immunotherapeutics. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.11.

See today’s best-performing stocks on TipRanks >>

Hinge Health, Inc. Class A (HNGE)

Truist Financial analyst Jailendra Singh maintained a Buy rating on Hinge Health, Inc. Class A today. The company’s shares closed last Friday at $63.62, close to its 52-week high of $66.55.

According to TipRanks.com, Singh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.1% and a 38.1% success rate. Singh covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Fortrea Holdings Inc., and Privia Health Group. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hinge Health, Inc. Class A with a $69.45 average price target, a 10.2% upside from current levels. In a report issued on June 5, TipRanks – xAI also upgraded the stock to Buy with a $70.00 price target.

MoonLake Immunotherapeutics (MLTX)

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $34.00. The company’s shares closed last Friday at $17.90.

According to TipRanks.com, Zhong has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.2% and a 34.1% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, CAMP4 Therapeutics Corporation, and Protagonist Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MoonLake Immunotherapeutics with a $30.91 average price target, implying a 65.7% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $45.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).